(CELC) Celcuity - Overview
Stock: Gedatolisib, CELsignia, PI3K, MTOR, Breast Cancer
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 66.6% |
| Relative Tail Risk | -16.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.68 |
| Alpha | 721.49 |
| Character TTM | |
|---|---|
| Beta | 1.068 |
| Beta Downside | 1.842 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.99% |
| CAGR/Max DD | 1.78 |
Description: CELC Celcuity January 16, 2026
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotech focused on targeted therapies for solid tumors in the U.S., anchored by its lead candidate Gedatolisib, a dual PI3K/mTOR inhibitor being evaluated in hormone-receptor-positive (HR+), HER2-negative breast cancer and metastatic castration-resistant prostate cancer (mCRPC). The company also commercializes the CELsignia diagnostic platform, which aims to match patients to appropriate therapies based on molecular profiling.
Key operational metrics show that Celcuity reported cash and equivalents of roughly $30 million at the end of 2023, with a monthly burn rate near $2 million, giving it an estimated runway of 12–14 months absent additional financing. The PI3K/mTOR inhibitor market is projected to exceed $5 billion by 2027, driven by unmet needs in endocrine-resistant breast cancer and the broader push for precision oncology, while FDA approval rates for Phase II oncology assets hover around 20 %.
Celcuity’s strategic partnership with Pfizer grants the latter development and commercialization rights to Gedatolisib, providing a potential pathway to scale if clinical data meet efficacy and safety thresholds; however, the company remains dependent on external funding and successful trial outcomes to de-risk its pipeline. For a deeper, data-driven view of Celcuity’s valuation dynamics, consider exploring ValueRay’s analytical tools.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -162.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA -3.16 > 1.0 |
| NWC/Revenue: 158.6k% < 20% (prev 107.2k%; Δ 51.4k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -144.7m > Net Income -162.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.8m) vs 12m ago 4.66% < -2% |
| Gross Margin: 31.27% > 18% (prev 0.47%; Δ 3080 % > 0.5%) |
| Asset Turnover: 0.07% > 50% (prev 0.08%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: -5.02 > 6 (EBITDA TTM -135.5m / Interest Expense TTM 27.0m) |
Altman Z'' 0.04
| A: 0.92 (Total Current Assets 475.5m - Total Current Liabilities 38.8m) / Total Assets 476.0m |
| B: -0.84 (Retained Earnings -397.9m / Total Assets 476.0m) |
| C: -0.36 (EBIT TTM -135.7m / Avg Total Assets 374.5m) |
| D: -0.78 (Book Value of Equity -281.0m / Total Liabilities 359.0m) |
| Altman-Z'' Score: 0.04 = B |
What is the price of CELC shares?
Over the past week, the price has changed by -2.44%, over one month by +1.65%, over three months by +43.87% and over the past year by +747.90%.
Is CELC a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CELC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.5 | 3.5% |
| Analysts Target Price | 110.5 | 3.5% |
| ValueRay Target Price | 126.2 | 18.2% |
CELC Fundamental Data Overview February 07, 2026
Revenue TTM = 275.3k USD
EBIT TTM = -135.7m USD
EBITDA TTM = -135.5m USD
Long Term Debt = 320.2m USD (from longTermDebt, last quarter)
Short Term Debt = 96.0k USD (from shortTermDebt, last quarter)
Debt = 320.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 246.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.69b USD (4.83b + Debt 320.3m - CCE 455.0m)
Interest Coverage Ratio = -5.02 (Ebit TTM -135.7m / Interest Expense TTM 27.0m)
EV/FCF = -32.37x (Enterprise Value 4.69b / FCF TTM -144.9m)
FCF Yield = -3.09% (FCF TTM -144.9m / Enterprise Value 4.69b)
FCF Margin = -52.6k% (FCF TTM -144.9m / Revenue TTM 275.3k)
Net Margin = -59.1k% (Net Income TTM -162.7m / Revenue TTM 275.3k)
Gross Margin = 31.27% ((Revenue TTM 275.3k - Cost of Revenue TTM 189.3k) / Revenue TTM)
Gross Margin QoQ = 50.0% (prev none%)
Tobins Q-Ratio = 9.85 (Enterprise Value 4.69b / Total Assets 476.0m)
Interest Expense / Debt = 5.42% (Interest Expense 17.4m / Debt 320.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.2m (EBIT -135.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.26 (Total Current Assets 475.5m / Total Current Liabilities 38.8m)
Debt / Equity = 2.74 (Debt 320.3m / totalStockholderEquity, last quarter 117.0m)
Debt / EBITDA = -1.82 (negative EBITDA) (Net Debt 246.1m / EBITDA -135.5m)
Debt / FCF = -1.70 (negative FCF - burning cash) (Net Debt 246.1m / FCF TTM -144.9m)
Total Stockholder Equity = 90.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.45% (Net Income -162.7m / Total Assets 476.0m)
RoE = -179.0% (Net Income TTM -162.7m / Total Stockholder Equity 90.9m)
RoCE = -33.00% (EBIT -135.7m / Capital Employed (Equity 90.9m + L.T.Debt 320.2m))
RoIC = -43.78% (negative operating profit) (NOPAT -107.2m / Invested Capital 244.9m)
WACC = 9.50% (E(4.83b)/V(5.15b) * Re(9.85%) + D(320.3m)/V(5.15b) * Rd(5.42%) * (1-Tc(0.21)))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.49%
Fair Price DCF = unknown (Cash Flow -144.9m)
EPS Correlation: 7.73 | EPS CAGR: 18.99% | SUE: 4.0 | # QB: 2
Revenue Correlation: 36.00 | Revenue CAGR: 72.38% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.12 | Chg30d=-0.095 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-4.52 | Chg30d=-0.240 | Revisions Net=-2 | Growth EPS=-23.1% | Growth Revenue=+0.0%